Answers are grounded in this paper and cite their sources.
Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic disease in individuals with no exogenous factors of toxic liver damage caused by the accumulation of lipids in the cellular elements that make up the liver lobule. NAFLD is a rapidly growing global health problem associated with increased morbidity and mortality. In recent years, the close relationship between NAFLD and cardiometabolic diseases has been emphasized, which is related to the common pathogenetic mechanisms of their development. Weight loss and lifestyle changes are the mainstay of treatment, but in most cases there is a need to introduce pharmacological therapy strategies. This review presents current data on epidemiology, pathophysiological aspects of the development and treatment of NAFLD, examines the relationship of hypertriglyceridemia in the development of NAFLD and the possibility of complex lipid-lowering therapy in improving the course of liver dysfunction.
No takes yet. Share an insight, caveat, or question.
Demidova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: